Clinical trial to study the role of Vitamin B3 in recovery of patients having Acute Kidney Injury
- Conditions
- Health Condition 1: N179- Acute kidney failure, unspecified
- Registration Number
- CTRI/2022/03/040892
- Lead Sponsor
- Department of Nephrolog
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Age between 18 â?? 70 years
Diagnosis of community-acquired AKI
Pre-existing CKD with baseline CKD EPI eGFR <60ml/min/1.73m2 prior to the onset of illness.
High likelihood of underlying CKD as determined by treating physician based on clinical and laboratory parameters.
Suspected or biopsy proven glomerulonephritis as a cause of AKI.
Obstructive nephropathy as a cause of AKI.
Solid-organ or bone marrow transplant recipients.
High likelihood of re-hospitalization or death in the following 4 months as ascertained by treating physician.
Suspected or diagnosed case of decompensated chronic liver disease or AST/ ALT more than 5 times of upper limit of normal.
Suspected or diagnosed case of heart failure with functional class 3 or 4.
Past or present diagnosis of malignancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome measure will be the renal recovery at 4-month in patients having community-acquired AKITimepoint: 4 month
- Secondary Outcome Measures
Name Time Method Secondary outcome measures will include <br/ ><br>a.all-cause mortality <br/ ><br>b.urine quinolate to tryptophan ratio after niacinamide supplementation <br/ ><br> <br/ ><br>Safety outcome measures will include: <br/ ><br>a.side effects of niacinamide <br/ ><br>b.hypersensitivity reaction after administration of intervention drug <br/ ><br>Timepoint: 1 month and 4 month